ATRX and cancer: In the past decade, high-throughput exon and whole-genome sequencing has shown that mutations in the histone protein ATRX and its partner DAXX are associated with an increased incidence of ALT activation in various cancer types (Heaphy et al., 2011; Schwartzentruber et al., 2012; Ceccarelli et al., 2016).